Coronavirus: Medical Treatments

(asked on 1st June 2022) - View Source

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, with reference to the US FDA's withdrawal of authorisation for the use of Sotrovimab for treatment of covid-19 on 5 April 2022, what steps he is taking to ensure the (a) stringency and (b) consistency of his Department's reviews of (i) Evusheld and (ii) other covid-19 treatments.


Answered by
Maggie Throup Portrait
Maggie Throup
This question was answered on 21st June 2022

The Antivirals and Therapeutics Taskforce engages with other nations to share learning on the use, deployment and evaluation of COVID-19 therapeutics and antivirals which may inform policy. The UK Health Security Agency is monitoring the effectiveness of all COVID-19 therapeutics, including sotrovimab. The RAPID C-19 collaborative, the National Health Service and other relevant experts provide advice to the United Kingdom Chief Medical Officers on whether treatments should be recommended for deployment, taking account of all available evidence.

The Department is currently reviewing prophylaxis and the efficacy of Evusheld. The Therapeutics Clinical Review Panel provides advice on the appropriate patient cohorts for potential new COVID-19 therapies, including preventative treatments. Final clinical policies and eligibility would be proposed by the NHS and agreed by the UK Chief Medical Officers.

Reticulating Splines